AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29625762
Drug: PCT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT and antidepressants
Trial: 6125562
Drug: Antidepressants alone
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants alone
Trial: 29625762
Drug: PCT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT with tapering of antidepressants
Trial: 26220763
Drug: Probiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bifidobacterium lactis, Bifidobacterium longum, or a combination of both)
Trial: 26220763
Drug: Probiotics (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bifidobacterium supplements)
Trial: 24983746
Drug: Semagacestat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semagacestat (100 mg and 140 mg)
Trial: 19892338
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy (group 1)
Trial: 9744372
Drug: Latanoprost treatment
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost treatment
Trial: 16822992
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (ECF regimen: epirubicin 50 mg/m², cisplatin 60 mg/m², fluorouracil 200 mg/m²/day for 21 days) and surgery
Trial: 16822992
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (ECF regimen)
Trial: 8956299
Drug: Nifedipine infusion
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine infusion from isolation of aorta until end of surgery (group A)
Trial: 8956299
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine infusion over the same surgical course (group B)
Trial: 1286501
Drug: Flumazenil (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (maximum dose of 1 mg, administered intravenously at 0.2 mg at 1-minute intervals)
Trial: 1286501
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml administered at 1-minute intervals)
Trial: 3927551
Drug: Leuprolide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide (1 mg per day, subcutaneous injection)
Trial: 3927551
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) (3 mg per day, oral)
Trial: 10453373
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (maximum dose 22 mg/day)
Trial: 7598064
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (1.47 g protein.kg body cell mass‐1.d‐1)
Trial: 7598064
Drug: Adequate-protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate-protein diet (2.94 g protein.kg body cell mass‐1.d‐1)
Trial: 31823206
Drug: Topical Low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Low Dose Preservative-Free Hydrocortisone
Trial: 30640654
Drug: Intravenously applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously applied morphine
Trial: 19683639
Drug: Percutaneous closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous closure of the left atrial appendage (LAA) and subsequent discontinuation of warfarin (n=463)
Trial: 19683639
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment with a target international normalised ratio between 2.0 and 3.0 (n=244)
Trial: 16320926
Drug: L-arginine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (7.5 g in 500 ml of cardioplegic solution)
Trial: 7714648
Drug: Pneumatic sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic sequential leg compression devices (PSLCDs)
Trial: 2522110
Drug: Sulpiride treatment
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride treatment
Trial: 31982695
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neutrophil chemotaxis activity with mHLA-DR, CD-11b expression, presepsin, and SOFA score
Trial: 25425655
Drug: Budesonide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days)
Trial: 8776122
Drug: Intradermal pins
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal pins
Trial: 2060255
Drug: 2% MK-927
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% MK-927 (1.2 mg) q.i.d.
Trial: 2060255
Drug: 1.8% sezolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8% sezolamide (1.1 mg) q.i.d.
Trial: 31124272
Drug: rFVIIa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (100 ± 20 μg/kg dose)
Trial: 27139057
Drug: Chemotherapy (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (1000 mg/m2 weekly of gemcitabine)
Trial: 27139057
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus erlotinib (100 mg/d)
Trial: 26017589
Drug: Nitroglycerin ointment
RxNorm normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin ointment (45 mg) applied to mastectomy skin at the time of surgical dressing
Trial: 22236639
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound therapy (Control)
Trial: 20068494
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg x kg(-1) body mass)
Trial: 27548794
Drug: Caffeine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (various doses)
Trial: 11838628
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment (50 to 200 mg/day) during the acute phase
Trial: 11838628
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with sertraline
Trial: 11838628
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of sertraline (double-blind)
Trial: 7677455
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) + Glutamine (GLN) + Diet (DIET)
Trial: 7677455
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy with GH + GLN + DIET
Trial: 2119392
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg leuprolide acetate (GnRH agonist)
Trial: 27484017
Drug: Staloral® (12000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staloral® (12000 BAU/ml)
Trial: 27484017
Drug: Soluprick® (10300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluprick® (10300 BAU/ml)
Trial: 27484017
Drug: Reference extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference extract (10000 BAU/ml)
Trial: 18495456
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment with varying total choline (344-486 mg/day), betaine (122-349 mg/day) and/or folate (400-800 microg dietary folate equivalents/day) for 12 weeks
Trial: 11883349
Drug: 10‐mg PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg PGE2 vaginal insert
Trial: 11883349
Drug: 3‐mg PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mg PGE2 tablets (administered twice at six‐hour intervals)
Trial: 11883349
Drug: 3‐mg PGE2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐mg PGE2 tablets
Trial: 2115444
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (10 mg(24 h)‐1)
Trial: 2115444
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (mean dose: 40 +/‐ 9 micrograms min‐1)
Trial: 7355391
Drug: Cimetadine (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetadine (three preoperative doses)
Trial: 7355391
Drug: Glycopyrrolate (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate (0.005 mg/kg)
Trial: 31711605
Drug: i.v. dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. dexamethasone 2 mg
Trial: 31711605
Drug: i.v. dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. dexamethasone 4 mg
Trial: 26921136
Drug: Vaginal progesterone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone, 200 mg daily from 22-24 to 34 weeks of gestation
Trial: 24052092
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (10-week intervention)
Trial: 20209088
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (≥800 IU orally daily)
Trial: 18520275
Drug: Modified forearm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified forearm minidose intravenous regional anesthesia (IVRA)
Trial: 18520275
Drug: Conventional minidose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional minidose intravenous regional anesthesia (IVRA)
Trial: 15925082
Drug: Tadalafil 20mg
RxNorm normalized name: TADALAFIL 20MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tadalafil 20mg on demand (maximum one dose per day before sexual activity)
Trial: 7579093
Drug: Plasma clearance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma clearance of iohexol (single iv dose)
Trial: 19779705
Drug: Oral cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporin A
Trial: 26493396
Drug: Continuous caudal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous caudal epidural bupivacaine 0.125 % with fentanyl, IV fentanyl, and paracetamol
Trial: 26493396
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl and paracetamol
Trial: 20061693
Drug: Intraluminal vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraluminal vancomycin (500 mg infusion via both lumens of the Permcath and antibiotic lock of 1.5 mL every 48 hours) and intravenous ceftriaxone (1 g every 12 hours for 7 days) followed by oral antibiotics for three weeks
Trial: 20061693
Drug: Intravenous vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vancomycin (500 mg) and daily intravenous amikacin (100-150 mg)
Trial: 18834241
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy before 21 weeks' gestation
Trial: 2699207
Drug: d-fenfluramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (15 mg p.o. twice daily)
Trial: 25825855
Drug: 4‐week outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐week outpatient treatment by the same multidisciplinary team
Trial: 21764118
Drug: Sertraline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (150 mg per day)
Trial: 21764118
Drug: Mirtazapine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (45 mg)
Trial: 19517423
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg venlafaxine tablets
Trial: 17082465
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy and ongoing medical care (Control)
Trial: 7991719
Drug: standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard dose of neuroleptic
Trial: 2604291
Drug: Combined formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined formulation of isoniazid (125 mg), rifampin (100 mg), and pyrazinamide (375 mg)
Trial: 2604291
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations of isoniazid, rifampin, and pyrazinamide
Trial: 2604291
Drug: Combined formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined formulation
Trial: 26106962
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations
Trial: 23271193
Drug: Drug Effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Effects Questionnaire (DEQ) for amphetamine
Trial: 23271193
Drug: Drug Effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Effects Questionnaire (DEQ) for nicotine
Trial: 23271193
Drug: Drug Effects
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Effects Questionnaire (DEQ) for alcohol
Trial: 16835255
Drug: Intra-articular magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular magnesium sulphate (MgSO4) 10 ml (50 mg/ml)
Trial: 16835255
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml (Control Group)
Trial: 11808835
Drug: Smoking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking reduction (4-8 cigarettes daily)
Trial: 8775880
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy with aspirin
Trial: 8775880
Drug: Novel antiplatelet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel antiplatelet and antithrombotic agents
Trial: 2342740
Drug: Preterm birth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm birth prevention program consisting of risk scoring, intensive weekly observation including cervical examinations, and detailed education about preterm labor signs and symptoms.
Trial: 2342740
Drug: Preterm birth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm birth prevention program (treatment group).
Trial: 7449720
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Quinupramine
Trial: 7449720
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Quinupramine
Trial: 6832466
Drug: Indobufen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (200 mg single oral dose)
Trial: 30935809
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT), 0.340 mJ/mm2, 2000 shots
Trial: 25377370
Drug: Trazodone (hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (hypnotic doses)
Trial: 25377370
Drug: Zopiclone (hypnotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (hypnotic agent)
Trial: 18946743
Drug: Cholestyramine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 2 g BID, methimazole, and propranolol
Trial: 18946743
Drug: Cholestyramine 1
RxNorm normalized name: CHOLESTYRAMINE 1GM TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 1 g BID, methimazole, and propranolol
Trial: 11838627
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (100 mg/day increasing to 400 mg/day over 4 weeks)
Trial: 25920468
Drug: Church-based diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Church-based diabetes self-management program (eight weekly group classes led by trained lay leaders)
Trial: 23630211
Drug: G‐CSF throughout
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF throughout all chemotherapy cycles
Trial: 23630211
Drug: G‐CSF during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF during the first two cycles only
Trial: 17695603
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide (HP) concentrations ranging from 15% to 35% with treatment contact times of 15 to 60 minutes.
Trial: 15096085
Drug: Lamotrigine (50‐400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (50‐400 mg/day fixed dose or 100‐400 mg/day flexible dose)
Trial: 15096085
Drug: Lithium (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (serum level of 0.8‐1.1 mEq/L)
Trial: 12017403
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg alone
Trial: 12017403
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Sumatriptan 50 mg + Clarithromycin 500 mg)
Trial: 12017403
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Sumatriptan alone and Combination treatment)
Trial: 2373130
Drug: Energy deficient
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy deficient diet (daily energy intake 4.3 MJ; daily protein intake 0.94 g/kg)
Trial: 2373130
Drug: Protein deficient
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein deficient diet (daily energy intake 11.4 MJ; daily protein intake 0.31 g/kg)
Trial: 2373130
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (daily energy intake 12.0 MJ; daily protein intake 1.52 g/kg)
Trial: 7032558
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine tablets (MST-1; 2 x 10 mg)
Trial: 7032558
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine sulphate in solution (20 mg)
Trial: 7032558
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine tablets (MST-1)
Trial: 25196040
Drug: Caffeine-glucose combination
RxNorm normalized name: caffeine / glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-glucose combination (60g glucose + 40mg caffeine)
Trial: 22120913
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy (deferasirox)
Trial: 21194441
Drug: Intra-articular interleukin-1
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular interleukin-1 receptor antagonist (IL-1Ra) therapy
Trial: 14561016
Drug: Cardioselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta-blockers
Trial: 2564723
Drug: Terazosin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin monotherapy
Trial: 2564723
Drug: Methyclothiazide (MCTZ)
RxNorm normalized name: Methyclothiazide
DrugBank: Methyclothiazide (DB00232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyclothiazide (MCTZ) monotherapy
Trial: 2564723
Drug: Terazosin/MCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin/MCTZ combination therapy
Trial: 2564723
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs. monotherapy
Trial: 28058491
Drug: Hypomethylating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating therapy with decitabine
Trial: 26248593
Drug: Simeprevir (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (150 mg for 7 days)
Trial: 26248593
Drug: Simeprevir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir (200 mg single dose)
Trial: 24051622
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (SEQ) with chemical nail avulsion, RV4104A ointment (40% urea), ciclopirox cream for 8 weeks, and ciclopirox nail lacquer for 25 weeks
Trial: 24051622
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (SEQ)
Trial: 20444308
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg/kg) followed by lactate (10 mg/kg)
Trial: 17036484
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic drug (control group)